The use of the proteasome inhibitor bortezomib does not increase overall treatment costs in myeloma compared to previous conventional therapies, a South Australian study has found. An analysis of real-world treatment costs for 70 patients treated with bortezomib in Adelaide since 2012 found that overall expenditure on hospitalisation was no greater than costs for a ...
Bortezomib does not increase treatment costs in myeloma
By Michael Woodhead
6 Feb 2020